{"prompt": "['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', 'menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled', 'crossover study. Haemophilia 2002; 7: 787-93.', '36.', 'Foster PA. The reproductive health of women with von Willebrand disease unresponsive to', 'DDAVP: results of an international survey (ISTH). Thromb Haemost 1995; 74: 784-90.', '37.', 'Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine', 'system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004;', '111: 1425-8.', '38.', 'National Hemophilia Foundation. MASAC Recommendations regarding girls and women with', 'inherited bleeding disorders: Recommendation No. 197, 2010.', '39.', 'Turecek PL, Schrenk G, Rottensteiner H, Varadi K, Bevers E, Lenting P, Ilk N, Sleytr UB, Ehrlich HJ,', 'Schwarz HP. Structure and function of a recombinant von Willebrand factor drug candidate. Semin', 'Thromb Hemost 2010; 36: 510-21.', '40.', 'Medical Product Safety. In Healthy People 2010. 2003: 17:3-19 http://www.health.gov/ healthy', 'people.', '41.', 'Personal communication, Byams V, Centers for Disease Control, Division of Blood Disorders (CDC),', 'Atlanta GA, December 13, 2010.', '42.', 'Budde U, Metzner HJ, Muller HG. Comparative analysis and classification of von Willebrand', 'factor/ factor VIII concentrates: impact on treatment of patients with von Willebrand disease.', 'Semin Thromb Haemost 2006; 32: 626-35.', '43.', 'Tranexamic acid (Lysteda) for treatment of menorrhagia. The Medical Letter 2010; 1342: 54. 39-', '43.', '44.', 'Ware JE, Snow K, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide.', 'The Health Institute, Boston MA, 1993.', '45.', 'Ware JE. SF-36 Health survey update. Spine 2000; 25: 3130-9.', '46.', 'Ruta DA, Garratt Am, Chadha YC, Flett GJ, Hall MH, Russell IT. Assessment of patients with', 'menorrhagia: how valid is a structured clinical history as a measure of health status: Quality of', 'Life Research 1995; 4: 33-40.', '47.', 'CDC HRQoL-14 \"Healthy Days Measure\". National Center for Chronic Disease Prevention and', 'Health Promotion, Division of Population Health, Center for Disease Control and Prevention,', 'Altanta GA. http://www.cdc.gov/hrqol/hyrqol14_measure.htm.', '48.', 'Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population.', 'Appl Psychol Measurement 1977; 1: 387.', '49.', 'National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03,', 'June 14, 2010, http://ctep.cancer.gov/forms/CTCAEv4.pdf', '50.', 'Fitzmaurice GM, Laird NM, Ware JH. Repeated measures and related designs, in Applied', 'Longitudinal Analysis, 2nd Edition, 2011, pp 611-626, Wiley & Sons, Hoboken NJ.', '54']['<Insert site letterhead or logo, first page only>', 'CONSENT TO ACT AS A SUBJECT IN A RESEARCH STUDY', 'TITLE:', 'Prospective, Randomized, Crossover Trial Comparing Recombinant Von', 'Willebrand Factor (rVWF) VS. Tranexamic Acid (TA) to Minimize Menorrhagia in', 'Women with Type 1 Von Willebrand Disease: The VWD Minimize Study', 'VERSION: 1.0 / 19Mar2018', 'PRINCIPAL INVESTIGATOR:', '<Insert investigator name and contact information for your', 'site:', 'SOURCE OF SUPPORT:', 'National Heart, Lung, Blood Institute,', 'National Institutes of Health', 'Why is this research being done?', 'You are being asked to participate in a research study that compares the use of recombinant', 'von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda\u00ae) in women with von', 'Willebrand Disease (VWD) who have heavy monthly periods. von Willebrand disease is a', 'common genetic trait passed on in families (called inherited) bleeding disorder (or bleeding', 'disease) that occurs in 3% of the population. It is caused by deficient or defective von', 'Willebrand factor (VWF). Most people with VWD are treated with DDAVP (desmopressin),', 'which is a protein given by vein or as an intranasal spray to treat bleeding symptoms. The', 'problem is that some patients do not respond to DDAVP, or the response may be limited. This is', 'because after three days, the stores of VWF become low (or depleted). Tranexamic acid is', 'another treatment for menorrhagia, but it is less effective than DDAVP. Thus better treatments', 'are needed for individuals with VWD.', 'In two clinical trials, rVWF has been shown to be safe and effective in treating and preventing', 'bleeds in patients with VWD. Among women with menorrhagia in those trials, it also reduce', 'menstrual bleeding. The purpose of this study is to compare how well recombinant VWF (rVWF)', 'alone versus TA alone reduces bleeding in women with heavy monthly periods. rVWF is', 'licensed by the U.S. Food and Drug Administration (FDA) for the treatment and prevention of', 'bleeding, including menorrhagia (heavy monthly periods), in people with von Willebrand disease', '(VWD).', 'In the studies above, rVWF was given by intravenous (in a vein) infusion, reduced bleeding, and', 'was safe and well-tolerated. In a survey of 16 hemophilia treatment centers, VWF concentrate', 'has been used for menorrhagia only after first and second line treatment fail: in all 13 subjects', 'receiving VWF there was reduction in heavy menstrual bleeding. In six published studies of', 'rVWF or plasma-derived (pd) VWF concentrate, including two prospective, two retrospective', 'and two observational studies of 455 VWD subjects, a total of 88 women received VWF 36-50', 'IU/kg for 1-6 days with reduction in menstrual bleeding in all women, and no adverse effects.', 'Tranexamic acid (LystedaR) in this study is taken as a pill by mouth three times daily. It is', 'licensed by the FDA for the treatment of menorrhagia.', 'Page 1 of 13', 'University Of Pittsburgh', 'Approval Date: \"Approval Date\"', 'IRB #: \"IRBNo\"', 'Institutional Review Board', 'Renewal Date: \"Renewal Date\"']\n\n###\n\n", "completion": "END"}